From reactive to proactive: Continuous protein monitoring for preventive health care

Continuous biomarker monitoring is revolutionizing chronic disease management, with glucose monitoring for diabetes as the primary example. Given the success of this approach, a transition to continuous protein monitoring (CPM, a real-time, implantable or wearable technology) could similarly advance precision medicine. In this work, we review state-of-the-art CPM platforms and their prospective clinical impact across both chronic disorders-metabolic, cardiovascular, autoimmune, and neurodegenerative-and acute crises, such as sepsis and transplant dysfunction. We also highlight remaining barriers to widespread adoption, including sensor stability, robust machine learning models for live interpretation, and responsible data handling for patient privacy. With continued engineering and clinical validation, emerging biosensor technologies could transform disease management, facilitating earlier interventions and individualizing treatment strategies, ultimately improving patient outcomes.